• Mon. May 23rd, 2022

4 Finance News

Finance News

Top Tags

Protalix BioTherapeutics to Reveal Very First Quarter 2022 Financial and Organization Outcomes Teleconference on May 16, 2022 


May 9, 2022


Business to host teleconference and webcast at 8:30 a.m. EDT

CARMIEL, Israel, May 9, 2022/ PRNewswire/– Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical business concentrated on the advancement, production and commercialization of recombinant restorative proteins produced by its exclusive ProCellEx ® plant cell-based protein expression system, today revealed that it will launch its monetary outcomes for the very first quarter 2022 and supply an organization upgrade on Monday, May 16, 2022.

Management will host a teleconference with financiers to go over the monetary outcomes and supply an upgrade on current business and medical advancements at 8:30 a.m. Eastern Daytime Time (EDT).

Teleconference Information:

Monday, May 16, 2022, 8:30 a.m. Eastern Daytime Time (EDT)
. Domestic: 877-423-9813
. International: 201-689-8573
. Conference ID: 13729993

Webcast Information:

The conference will be webcast live from the Business’s site and will be readily available by means of the following links:

Business Link: https://protalixbiotherapeutics.gcs-web.com/events0
. Webcast Link: Registration– https://tinyurl.com/3b4tmnr9
. Conference ID: 13729993

Please access the sites a minimum of 15 minutes ahead of the conference to sign up, download and set up any required audio software application.

The teleconference will be readily available for replay for 2 weeks on the Occasions Calendar of the Financiers area of the Business’s site, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical business concentrated on the advancement and commercialization of recombinant restorative proteins revealed through its exclusive plant cell-based expression system, ProCellEx. Protalix was the very first business to get U.S. Fda (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix’s special expression system represents a brand-new approach for establishing recombinant proteins in an industrial-scale way.

Protalix’s very first item made by ProCellEx, taliglucerase alfa, was authorized by the FDA in Might 2012 and, consequently, by the regulative authorities of other nations. Protalix has actually certified to Pfizer Inc. the around the world advancement and commercialization rights for taliglucerase alfa, omitting Brazil, where Protalix keeps complete rights.

Protalix’s advancement pipeline includes exclusive variations of recombinant restorative proteins that target developed pharmaceutical markets, consisting of the following item prospects: pegunigalsidase alfa, a customized supported variation of the recombinant human α– Galactosidase– A protein for the treatment of Fabry illness; alidornase alfa or PRX– 110, for the treatment of numerous human breathing illness or conditions; PRX– 115, a plant cell-expressed recombinant PEGylated uricase for the treatment of refractory gout; PRX– 119, a plant cell-expressed long action DNase I for the treatment of NETs-related illness; and others. Protalix has actually partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the advancement and commercialization of pegunigalsidase alfa.

Financier Contact
. Chuck Padala, Handling Director
. LifeSci Advisors
. +1 -646 -627 -8390
. chuck@lifesciadvisors.com

Cision View initial material: https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2022-financial-and-business-results-conference-call-on-may-16-2022-301542441.html

SOURCE Protalix BioTherapeutics, Inc.

. Business Codes: AMEX: PLX, Frankfurt: PBDA, Dusseldorf: PBD, TelAviv: PLX, Stuttgart: PBD, Berlin: PBDA

Source link .

Leave a Reply

Your email address will not be published.